{"id":"k-924-ld","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL5934111","moleculeType":null,"molecularWeight":"554.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"K-924 LD acts as a dopamine receptor agonist with affinity for D2 and D3 receptors, formulated as a long-acting depot or extended-release preparation to enable less frequent dosing. This mechanism is intended to improve treatment adherence and maintain consistent dopaminergic signaling in conditions where dopamine deficiency or dysregulation is pathogenic.","oneSentence":"K-924 LD is a long-acting dopamine D2/D3 receptor agonist designed to provide sustained dopaminergic activity for extended treatment intervals.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:41.967Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT04289649","phase":"PHASE3","title":"K-924 Phase III Confirmatory Study","status":"COMPLETED","sponsor":"Kowa Company, Ltd.","startDate":"2020-04-02","conditions":"Hypercholesterolemia","enrollment":293},{"nctId":"NCT04289662","phase":"PHASE3","title":"K-924 Phase III Long Term Study","status":"COMPLETED","sponsor":"Kowa Company, Ltd.","startDate":"2020-03-23","conditions":"Hypercholesterolemia","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"K-924 LD","genericName":"K-924 LD","companyName":"Kowa Company, Ltd.","companyId":"kowa-company-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"K-924 LD is a treatment being studied in a Phase III clinical trial for hypercholesterolemia. The trial, NCT04289649, is a randomized, multicenter study comparing K-924 LD to a placebo.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}